Telitacicept Shows Deepening, Durable Response in Myasthenia Gravis

17 Oct 2026 0 comments

New 48-week phase 3 data show many patients with generalized myasthenia gravis reached minimal symptom expression on telitacicept, and most who did sustained it.

Source: NeurologyLive · Published 14 Oct 2026 · Imported 17 Oct 2026

Read the article

Comments

No comments yet.

Unrestricted

All comments are reviewed before being published. Most comments are approved unless they are clearly inappropriate or unsafe.

Comments

Leave a comment